|
|
| | SB 209670 Basic information |
| Product Name: | SB 209670 | | Synonyms: | SB 209670;(1S,2R,3S)-1-(1,3-BENZODIOXOL-5-YL)-3-[2-(CARBOXYMETHYLOXY)-4-METHOXYPHENYL]-5-PROPOXY-2,3-DIHYDRO-1H-INDENE-2-CARBOXYLIC ACID;SB209670, CID108002;1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-[2-(carboxymethoxy)-4-methoxyphenyl]-2,3-dihydro-5-propoxy-, (1S,2R,3S)-;SB209670,SB 209670;SB-209670, 10 mM in DMSO | | CAS: | 157659-79-5 | | MF: | C29H28O9 | | MW: | 520.53 | | EINECS: | | | Product Categories: | | | Mol File: | 157659-79-5.mol |  |
| | SB 209670 Chemical Properties |
| | SB 209670 Usage And Synthesis |
| Uses | SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty[1]. | | References | [1] E H Ohlstein, et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052-6. DOI:10.1073/pnas.91.17.8052 |
| | SB 209670 Preparation Products And Raw materials |
|